Evidence map›Paper›PMID 34775784›Full record

Trial reportCirculation2022

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.

Gerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, Luis M Ruilope, Peter Rossing, George L Bakris, Christoph Tasto, Amer Joseph, Peter Kolkhof, Andrea Lage and 2 more

3 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 145 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 4 pooled it
20.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07351864 phase4not yet recruitingstarted 2026, after this paper: background citation

Impact of Finerenone in Combination With Sodium Glucose Cotransporter-2 Inhibitor in Patients With Heart Failure

Ran2026Enrolled60Registered outcomes6Posted comparisons0ConditionsHeart FailureArmsdapagliflozine, Finerenone
PMID 38692445PMID 33264825other papers from this trial
Open the trial in the graph
NCT02545049 phase3completednot on this map

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care.

TypeinterventionalSponsorBayerRan2015 to 2021Enrolled7,352ConditionsDiabetic Kidney DiseaseArmsFinerenone (BAY94-8862), Placebo
NCT06143566 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Polypill Strategy for Prevention of Cardiomyopathy Among Patients With Diabetes at Risk of Heart Failure

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2024 to 2027Enrolled200ConditionsType 2 Diabetes, High Blood PressureArmsPolypill, Combined prescription of the individual medications
3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 4 syntheses or guidelines pooled it, 246 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Heart failure burden and care among cardiology inpatients: insights from the Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 6 countries.

Gerasimos FilippatosNational and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Greece (G.F.).ORCID 0000-0002-5640-0332
Stefan D AnkerDepartment of Cardiology (Charité Campus Virchow-Klinikum) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin (S.D.A.).ORCID 0000-0002-0805-8683
Rajiv AgarwalRichard L. Roudebush VA Medical Center and Indiana University, Indianapolis (R.A.).ORCID 0000-0001-8355-7100
Luis M RuilopeCardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain (L.M.R.).
Peter RossingSteno Diabetes Center Copenhagen, Gentofte, Denmark (P.R.).
George L BakrisDepartment of Medicine, University of Chicago Medicine, IL (G.L.B.).ORCID 0000-0003-1183-1267
Christoph TastoResearch and Development, Statistics and Data Insights (C.T.), Bayer AG, Wuppertal, Germany.
Amer JosephResearch and Development, Cardiology and Nephrology Clinical Development (A.J.), Bayer AG, Wuppertal, Germany.
Peter KolkhofPreclinical Research Cardiovascular, Pharmaceuticals, Research and Development (P.K.), Bayer AG, Wuppertal, Germany.
Andrea LageCardiology and Nephrology Clinical Development, Bayer SA, São Paulo, Brazil (A.L.).ORCID 0000-0002-9893-2759
Bertram PittDepartment of Medicine, University of Michigan School of Medicine, Ann Arbor (B.P.).
FIGARO-DKD Investigators
Bayer (Germany) · DEBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEMadrid Institute for Advanced Studies · ESNational and Kapodistrian University of Athens · GRRichard L. Roudebush VA Medical Center · USUniversidade de São Paulo · BRUniversity of Chicago · USUniversity of Copenhagen · DKUniversity of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic kidney disease and type 2 diabetes are independently associated with heart failure (HF), a leading cause of morbidity and mortality. In the FIDELIO-DKD (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease) and FIGARO-DKD (Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease) trials, finerenone (a selective, nonsteroidal mineralocorticoid receptor antagonist) improved cardiovascular outcomes in patients with albuminuric chronic kidney disease and type 2 diabetes. These prespecified analyses from FIGARO-DKD assessed the effect of finerenone on clinically important HF outcomes.

methodsPatients with type 2 diabetes and albuminuric chronic kidney disease (urine albumin-to-creatinine ratio ≥30 to <300 mg/g and estimated glomerular filtration rate ≥25 to ≤90 mL per min per 1.73 m

resultsOverall, 7352 patients were included in these analyses; 571 (7.8%) had a history of HF at baseline. New-onset HF was significantly reduced with finerenone versus placebo (1.9% versus 2.8%; hazard ratio [HR], 0.68 [95% CI, 0.50-0.93];

conclusionsThe results from these FIGARO-DKD analyses demonstrate that finerenone reduces new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, irrespective of a history of HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02545049.

Indexed as

AgedDiabetes Mellitus, Type 2FemaleHeart FailureHumansIncidenceMaleMiddle AgedNaphthyridinesRenal Insufficiency, ChronicfinerenoneNaphthyridinesaldosteronechronic kidney diseasefinerenoneheart failuremineralocorticoid receptor antagonisttype 2 diabetes

Identifiers

PMID34775784
PMCPMC8812430
OpenAlexW3212342864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.